Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — H1 2026 Earnings Presentation
19 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Jul 22, 2026
Slide 1: Earnings Presentation 1H 2026
Earnings Presentation 1H 2026 Jeddah | 22 July 2026
Slide 2: Disclaimer
2 Disclaimer This presentation has been prepared solely for use as an investor presentation for Jamjoom Pharmaceuticals Factory Company (the “Company”). By attending or by reading this presentation, you agree to be bound by the following limitations. The information contained in this presentation is
Slide 3: Financial Highlights
Financial Highlights Anwer Mohiuddin, CFO
Slide 4: Q2 Momentum Broadens Across Revenue, Gross Profit and Earnings
4 Financial Highlights Q2 Momentum Broadens Across Revenue, Gross Profit and Earnings Revenue (SARmn) EBITDA (SARmn) +12% 445 +7% 396 159 148 Solid rebound from 1Q26 growth of 5% despite slowdown in primary Higher commercial activities, KSA market increase in salesforce and R&D 37.5% expenditure 35.
Slide 5: Favorable Product Mix and Cost Discipline Fund Commercial Expansion
5 Financial Highlights Favorable Product Mix and Cost Discipline Fund Commercial Expansion Total Cost Of Revenue Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +14% +4% 30 4 2 285 7 2 1 323 250 310 2 Investing in future growth through commercial hiring, increased promotional activity &
Slide 6: Strong Revenue Contribution Drives EBITDA to SAR 346 Million
6 Financial Highlights Strong Revenue Contribution Drives EBITDA to SAR 346 Million EBITDA Movement YoY (SARmn) +8% 73 EBITDA Margin EBITDA Margin 37.3% 37.6% (13) 0 346 321 (30) (4) (2) +9% +4% +16% +10% +11% +0% 1H 25 Revenue Cost of revenue Selling & distribution General & administration Research
Slide 7: Scaling Working Capital to Support Continuous Growth
7 Financial Highlights Scaling Working Capital to Support Continuous Growth ▪ Improved inventory days drove a reduction in the cash conversion cycle (CCC) to 285 Cash Conversion Cycle (Days) days (-2.7% YoY), despite higher receivable days (DSO) which were offset by a reduction in inventory days (DI
Slide 8: Business and Strategy Highlights
Business and Strategy Highlights Tarek Hosni, CEO
Slide 9: 1H 2026 Highlights: Sustained Growth Through Disciplined Execution
Business and Strategy Highlights 1H 2026 Highlights: Sustained Growth Through Disciplined Execution Revenue EBITDA Net Profit FCF 927 +9% YoY 346 +8% YoY 306 +6% YoY 319 +14% YoY SAR SAR SAR SAR mn mn mn mn Revenue growth since IPO EBITDA growth since IPO Net profit growth since IPO FCF growth since
Slide 10: A Consistent Track Record Since Listing
Business and Strategy Highlights A Consistent Track Record Since Listing Revenue (SAR mn) Net Profit (SAR mn) +16% CAGR +21% CAGR 927 289 306 854 731 599 210 171 1H-23 1H-24 1H-25 1H-26 1H-23 1H-24 1H-25 1H-26 EBITDA Margin (%) Dividend per Share (SAR) +30% CAGR 2.20 37.6 37.3 34.7 1.50 1.46 33.2 1.
Slide 11: Outgrowing the Market: JP Growth Outpaces the Market Across Key Geographies
Business and Strategy Highlights Outgrowing the Market: JP Growth Outpaces the Market Across Key Geographies 2-year revenue CAGR: Jamjoom vs. total market (%) Takeaways KSA JP grew 21.7% vs a 13.2% market — Jamjoom Pharma Total market outgrowing at ~1.6x despite the market being inflated by weight-l
Slide 12: JP Growth Beats Declining KSA Retail Market To Reach Rank 2, YTD & MAT
Business and Strategy Highlights JP Growth Beats Declining KSA Retail Market To Reach Rank 2, YTD & MAT Key Takeaways YTD MAT JP grew 7.53 % vs (-0.71%) MKT, Jan–May 2026 MAT May 2026 despite: i. The market growth being Market PVT sales SAR 13,312 M Market PVT sales SAR 31,770 M inflated by weight-
Slide 13: JP Continues to Outperform the UAE Retail Sector With 27.6% YTD Growth
Business and Strategy Highlights JP Continues to Outperform the UAE Retail Sector With 27.6% YTD Growth YTD MAT Jan–May 2026 MAT May 2026 Market PVT sales AED 8.302 B Market PVT sales AED 19.2 B +8.56% Market PPG% +10.22% Market PPG% JP PVT sales AED 128.9 M JP PVT sales AED 283.9 M JP Rank #18 JP R
Slide 14: Consistent Growth Across Core TAs and Markets
14 Business and Strategy Highlights Consistent Growth Across Core TAs and Markets Revenue Contribution by Therapeutic Area, YoY (SARmn) Revenue Contribution by Country, YoY (SARmn) +9% 32 21 17 3 927 854 +9% (0) 20 6 19 927 Improved 34 Decline reflects distributor 854 Growth primarily led by effecti
Slide 15: Building the Future: 65-Strength Pipeline and 21 BD Agreements Signed
Business and Strategy Highlights Building the Future: 65-Strength Pipeline and 21 BD Agreements Signed New-product development pipeline (65 Products) Business development: signed & progressing 28 Under development 21 11 5 Already under SFDA Agreements signed Signed in 1H26 review 20 Ready for SFDA s
Slide 16: Six Priorities For The Six Months Ahead
Business and Strategy Highlights Six Priorities For The Six Months Ahead… 01 Sustain market outperformance across key therapeutic areas and markets 02 Complete the KAEC Facility acquisition and integration into JP’s manufacturing footprint 03 Incorporate and Operationalize the Jamjoom Pharma x Lifer
Slide 17: Outlook and Guidance
Jamjoom Pharma LojLé pgaa Outlook and Guidance
Slide 18: Reiterating Guidance Despite Saudi Market Slowdown And Geopolitical Impact
18 Outlook and Guidance Reiterating Guidance Despite Saudi Market Slowdown And Geopolitical Impact FY 26-27 Guidance Revenue growth 10-12% (CAGR) EBITDA margin 33-35% CAPEX 6-9% Dividend 50-60% payout subject to optimum capital allocation decision (semi-annual) Jamjoom Earnings Presentation - 22/07/
Slide 19: Q&A
Q&A Tarek Hosni, Chief Executive Officer Anwer Mohiuddin, Chief Financial Officer Muhammad Bin Khalid, Assoc. Director – Finance & IR
Jamjoom Pharmaceuticals Factory — H1 2026 Earnings Presentation on 6ix